ArticleDiabetes, obesity & metabolism2025
Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pharmacokinetics of Ertugliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) in Horses After Enteral Administration.Veterinary sciences · 2026Article
- Effect of preoperative SGLT2 inhibitor use on postoperative acute kidney injury in patients with type 2 diabetes undergoing surgery: A causal inference study using routinely collected data.Diabetes, obesity & metabolism · 2026Article
- Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsThe use and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in hospital are controversial due to the risk of ketoacidosis. We aimed to describe rates of ketosis, ketoacidosis, and acidosis in patients with type 2 diabetes treated with in-hospital SGLT2i use. MATERIALS AND
methodsSingle-centre retrospective cohort study of adult patients with type 2 diabetes admitted for >24 h. Rates of ketone testing, ketone levels, ketosis precipitants, and ketoacidosis and acidosis frequency were determined from examination of electronic medical records. Outcomes were described relative to the first dose of SGLT2i in hospital.
resultsThere were 1511 patients who received SGLT2i at any stage of admission; of these, 777 (51.4%) had ketone levels checked. Peak ketone levels after the first dose of SGLT2i were >1 mmol/L in 12.6% and >3 mmol/L in 2.8%. Eleven out of 12 patients with ketones >3 mmol/L post-SGLT2i had ketosis in the setting of a procedure or surgery, sepsis, reduced oral intake, or critical illness. No patient admitted with heart failure had a ketone level >2 mmol/L. Biochemical ketoacidosis occurred in 1.7% of SGLT2i users pre-first dose of SGLT2i and 0.7% after the first dose. Acidosis (irrespective of ketone levels) occurred in 16.8% before the first dose of SGLT2i and 5.5% after the first dose.
conclusionsKetosis following inpatient SGLT2i administration was infrequent and generally occurred in the setting of known precipitants. These results suggest that, in hospitalized patients selected by clinicians to receive SGLT2i, clinically significant ketone accumulation is low in prevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.